<DOC>
	<DOCNO>NCT01569438</DOCNO>
	<brief_summary>The purpose study assess efficacy single dose level AF-219 female subject moderate severe pain associate interstitial cystitis/bladder pain syndrome ( IC/BPS ) 4 week treatment .</brief_summary>
	<brief_title>The Safety Efficacy AF-219 Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome</brief_title>
	<detailed_description>This study double-blind , placebo-controlled , randomized trial design assess efficacy safety single dose level AF-219 female subject moderate severe IC/BPS . The study consist 4 phase : Screening , Baseline , Treatment , Follow-up .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Women Women child bear potential must pregnant study must use two form birth control Clinical evidence IC/BPS Have provide write informed consent History disease confuse IC/BPS Unable void spontaneously Immunosuppressant , intravesicular , nerve stimulator opioid treatment study certain period prior start study . Changes dose ElmironÂ® , antidepressant , alphaadrenergic antagonist , H1 antagonist , antimuscarinic treatment within certain period prior start study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>